Incidence of community acquired ESBL-producing bacteria among asymptomatic University students in Anambra State, Nigeria
This study was conducted to investigate the incidence of community acquired extended-spectrum β-lactamase (ESBL)-producing bacteria among asymptomatic students of Nnamdi Azikiwe University, Awka, Anambra State, South-East Nigeria. A total of 102 non-duplicate strains of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa were isolated from fecal samples (n=273) collected from the participating students. The isolates were subjected to antimicrobial susceptibility tests to determine their antimicrobial resistance profile. Their multiple antibiotic resistance (MAR) indices were also evaluated. Screening of the isolates for possible ESBL production was carried out by disk diffusion test using cefotaxime and ceftazidime disks. ESBL-production by the resistant strains was confirmed using the double-disk synergy test. Most of the isolates were found to be multi-drug resistant, as all K. pneumoniae and P. aeruginosa strains (100%), and 98.4% of the E. coli strains, had MAR indices ≥0.2. A total of 22 ESBL-producing bacterial species were confirmed, and the frequency of E. coli, K. pneumoniae and P. aeruginosa isolates among the ESBL-producing bacteria were n=20 (90.9%), n=2 (9.1%), and n=0 (0.0%) respectively. The total number of ESBL-producing bacterial strains isolated accounted for 8.1 % of the entire sample population. Although this prevalence rate may not indicate an alarming situation, it is important that the proliferation of ESBL-producing bacteria in the community be contained, since a high incidence of ESBL-producing organisms will create significant therapeutic problems in the near future. There is therefore need to develop strategies to reduce their spread in the community especially through monitoring, surveillance and proper detection protocol.
2. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public health concern. Lancet Infect Dis. 2008; 8: 159-166.
3. Raji MA, Jamal W, Ojemhen O, Rotimi VO. Point-surveillance of antibiotic resistance in Enterobacteriaceae isolates from patients in a Lagos Teaching Hospital, Nigeria. J Infect Public Health. 2013; 6: 431-437.
4. Mugnaioli C, Luzzaro F, De Luca F, Brigante G, Perilli M, Amicosante G, et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother. 2006; 50: 2700-2706.
5. Lee JH, Bae IK, Lee SH. New definitions of extended spectrum β-lactamase conferring worldwide emerging antibiotic resistance. Med Res Rev. 2011; 32: 216-232.
6. Agrawal P, Ghosh A, Kumar S, Basu B, Kapil K. Prevalence of extended spectrum β-lactamases among E. coli and K. pneumoniae isolates in tertiary care hospital. Indian J Pathol Microbiol. 2008; 51: 139-142.
7. Tansarli GS, Poulikakos P, Kapaskelis A, Falagas ME. Proportion of extended-spectrum β-lactamase (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence-systematic review. J Antimicrob Chemother. 2014; 69(5): 1177-1184.
8. Friedmann R, Raveh D, Zartzer E, Rudensky B, Broide E, Attias D, Yinnon AM. Prospective evaluation of colonization with extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing Enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol. 2009; 30: 534-542.
9. Yusha’u M, Aliyu HM, Kumurya AS, Suleiman K. Prevalence of extended spectrum β-lactamases (ESBLs) among Enterobacteriaceae in Murtala Mohammed Specialist Hospital, Kano, Nigeria. Bayero J Pure Appl Sci. 2010; 3(1): 169-172.
10. Afunwa RA, Odumegwu DC, Iroha IR, Esimone CO. Antimicrobial resistance status and prevalence rates of extended spectrum β-lactamase producers isolated from a mixed human population. Bosnian J Basic Med Sci. 2011; 11(2): 91-96.
11. Aibinu IE, Ohaegbulam VC, Adenipekun EA, Ogunsola FT, Odugbemi TO, Mee BJ. Extended spectrum β lactamase enzymes in clinical isolates of Enterobacter species from Lagos, Nigeria. J Clin Microbiol. 2003; 41: 2197-2200.
12. Akujobi CN, Ewuru CP. Detection of extended spectrum beta-lactamases in gram negative bacilli from clinical specimens in a teaching hospital in South-Eastern Nigeria. Niger Med J. 2010; 51: 141-146.
13. Okesola AO, Adeniji TW. Pattern of extended spectrum β-lactamase production among clinical isolates of Proteus Species in western Nigeria. World J Med Sci. 2010; 5(4): 94-97.
14. Iroha IR, Amadi SE, Adikwu MU, Esimone CO. Detection of plasmid borne extended spectrum β-lactamase enzymes in clinical isolates of Escherichia coli from a community general hospital. Int J Mol Med Adv Sci. 2008; 4(2): 46-49.
15. Iroha IR, Esimone CO, Neumann S, Marlinghaus L, Korte M, Szabados F, et al. First description of Escherichia coli producing CTX-M-15-extended spectrum beta-lactamase (ESBL) in out-patients from south eastern Nigeria. Annals Clin Microbiol Antimicrob. 2012; 11: 19.
16. Iroha IR, Okoye E, Osigwe CA, Moses IB, Ejikeugwu CP, Nwakaeze AE. Isolation, phenotypic characterization and prevalence of ESBL-producing Escherichia coli and Klebsiella species from orthopedic wounds in National Orthopedic Hospital Enugu (NOHE), South East Nigeria. J Pharma Care Health Sys. 2017; 4(4): 1-5.
17. Ejikeugwu C, Ikegbunam M, Ugwu C, Eze P, Iroha I, Esimone C. Phenotypic detection of Klebsiella pneumoniae strains - producing extended spectrum β-lactamase (ESBL) enzymes. Scholars Acad J Biosci. 2013; 1(1): 20-23.
18. Alabi OS, Oyenwe NE, Satoye KA, Adeleke OE. Prevalence of extended-spectrum β-lactamase producing isolates from asymptomatic bacteriuria among students in a tertiary institution in Ibadan, Nigeria. Nature Sci. 2014; 12(4): 111-114.
19. Cheesbrough M. District laboratory practice in tropical countries. Part 2, 2nd Edn. Cambridge University Press, 2006.
20. WHO. Basic laboratory procedures in clinical bacteriology. 2nd edn. Vandepitte J, Verhaegen J, Engbaek K, Rohner P, Piot P, Heuck CC, eds. World Health Organization (WHO), Geneva, 2003.
21. CLSI. Performance standards for antimicrobial susceptibility testing. 21 Informational Supplement. Clinical and Laboratory Standard Institute (CLSI). M100-S21, 2011; 31(1).
22. Riaz S, Faisal M, Hasnain S. Antibiotic susceptibility pattern and multiple antibiotic resistances (MAR) calculation of extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella species in Pakistan. Afr J Biotechnol. 2011; 10(33): 6325-6331.
23. Torimiro N. Extended-spectrum β-lactamase occurrence among Gram-negative bacilli isolated from urine of apparently healthy individuals at Obafemi Awolowo University, Ile-Ife, Nigeria. J Adv Microbiol. 2018; 8(4): 1-6.
24. Fadeyi A, Zumuk CP, Raheem RA, Nwabuisi C, Desalu OO. Prevalence and antibiotic susceptibility pattern of ESBL producing Klebsiella isolated from clinical specimens in a Nigerian tertiary hospital. Afr J Infect Dis. 2016; 10(1): 32-37.
25. Yah SC, Yusuf OE, Eghafona NO. Pattern of antibiotic usage by adult populations in the city of Benin, Nigeria. Scient Res Essay. 2008; 3: 81-85.
26. Tamuno I, Mohammed SI. Self-medication with antibiotics amongst students of a Nigerian Tertiary Institution. J Basic Appl Sci Res. 2011; 1: 1319-1326.
27. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci. 2015; 22(1): 90-101.
28. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008; 13(47): 19044.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.